Julia Rotow, MD

Articles

Future Directions in ALK-Positive and BRAF-Positive NSCLC Management

November 22nd 2024

Panelists discuss how advancements in targeted therapies and personalized medicine are crucial for addressing the pressing unanswered questions in the management of ALK-positive and BRAF-positive cancers.

Precision BRAF Therapy: Optimizing Dosing, Sequencing, and Toxicity Management in NSCLC

November 22nd 2024

Panelists discuss the role of immunotherapy in the treatment landscape for BRAF-positive NSCLC, considering factors influencing the choice between immunotherapy and targeted therapy, emerging therapies, ongoing clinical trials, and approaches to dosing, sequencing, and toxicity management for both ALK and BRAF inhibitors.

Long-Term Outcomes of BRAF-MEK Inhibitor Combinations

November 15th 2024

Panelists discuss recent data on progression-free survival (PFS) and duration of response (DOR) for BRAF-MEK inhibitor combinations, including encorafenib + binimetinib and dabrafenib + trametinib, while also addressing emerging safety signals, differences in response based on treatment lines, and considerations for dose modifications and sequencing strategies in clinical practice.

Combination Therapies in BRAF-Positive NSCLC

November 15th 2024

Panelists discuss their insights on current and emerging combination strategies in the treatment of BRAF-positive NSCLC, focusing on the integration of targeted therapies, immunotherapies, or both.

From Early Stage to Resistance: ALINA Study Insights and ALK Inhibitor Sequencing Strategies

November 8th 2024

Panelists discuss the findings from the ALINA study on adjuvant alectinib vs chemotherapy in resected ALK-positive NSCLC, considering how these results may influence early-stage management, sequencing strategies for ALK inhibitors, and the role of resistance mechanisms in treatment decisions.

Intracranial Efficacy of Next-Generation ALK-Targeted Therapies

November 8th 2024

Panelists discuss the efficacy of ALK inhibitors in treating brain metastases, referencing data from the REMARK study, the CROWN trial, ALTA-3, and ALTA-1L/brigatinib, among others.

Optimizing ALK-TKI Sequencing and Neurological Outcomes

November 1st 2024

Panelists discuss the circumstances under which they would consider switching patients on different first-line treatments to lorlatinib and outline approaches for CNS surveillance and management in ALK-positive patients.

Clinical Impact of ALK Inhibitor Data: Efficacy, Brain Metastases, and CNS Management Strategies

November 1st 2024

Panelists discuss how recent data influence treatment choices for ALK-positive NSCLC patients, highlighting specific patient factors that guide decisions and potential concerns regarding the use of lorlatinib as first-line therapy.

CROWN and BRIGHTSTAR Studies: Latest Data Insights

October 25th 2024

Panelists discuss the key findings from the latest data from the CROWN and BRIGHTSTAR studies, emphasizing efficacy end points and comparing the effectiveness of these regimens with that of others in the treatment landscape for ALK-positive NSCLC.

Molecular Testing and First-Line Treatment Selection in ALK-Positive NSCLC

October 25th 2024

Panelists discuss the importance of molecular testing in NSCLC, particularly for ALK rearrangements, and explore how recent advancements and emerging technologies are shaping first-line treatment selection for ALK-positive patients.

Patient Selection and Sequencing of NSCLC ADCs

August 19th 2024

The panel examines which patient populations might benefit most from treatment with datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, and patritumab deruxtecan (HER3-DXd). Additionally, they explore potential sequencing strategies for these antibody-drug conjugates in second-line and later treatment settings.

Mitigating Toxicities of Dato-DXd, Sacituzumab Govitecan, and HER3-DXd

August 12th 2024

Benjamin Levy, MD, compares the common toxicities associated with datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, and patritumab deruxtecan (HER3-DXd), and shares practical tips for managing these toxicities in the clinical setting to optimize patient care and minimize adverse effects.

Key ADC Studies at ASCO 2024

August 12th 2024

Julia Rotow, MD, highlights and discusses other notable antibody-drug conjugate (ADC) data presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting, providing insights into the potential impact of these findings on the evolving treatment landscape for non-small cell lung cancer (NSCLC).

Rotow Reviews Key Updates on the Management of CNS Metastases in NSCLC

August 8th 2024

Dr Rotow discusses data that demonstrated the central nervous system activity of datopotamab deruxtecan and osimertinib in patients with NSCLC.

Challenges and Learnings from EVOKE-01

August 5th 2024

Benjamin Levy, MD, provides an overview of the rationale and study design for the EVOKE-01 trial, which evaluates the efficacy and safety of sacituzumab govitecan in patients with non-small cell lung cancer who have experienced disease progression following treatment with platinum-based chemotherapy and checkpoint inhibitors.

Targeting of HER3: Insights from HERTHENA-Lung01

August 5th 2024

Helena A. Yu, MD, initiates a discussion on the role of HER3 in the development of resistance to EGFR-targeted therapies. She also examines the HERTHENA-Lung01 study and analyzes the emerging data from this trial.

Key Takeaways from TROPION Trials: Implications for NSCLC Treatment Landscape

July 29th 2024

Overview of TROP2 & Potential Role of TROP2-Directed ADCs in NSCLC

July 29th 2024

Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes

July 25th 2024

Julia Rotow, MD, discusses the importance of comprehensive biomarker testing for all patients with NSCLC.

ASCO 2024 Updates: Novel Approaches in NSCLC Therapy

July 22nd 2024

The panel explores promising novel therapies in the treatment landscape, focusing on new or recently presented data at the American Society of Clinical Oncology (ASCO) 2024 annual meeting, and share their insights on the potential impact of these therapies on future clinical practice.